Bektas Isik

Dr. Bektas Isik

Department of Internal Medicine, Adana City Training and Research Hospital, Adana, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
Verified
Journal Article
Closed access
HOHuseyin Ali Ozturk
Huseyin Ali Ozturk
EGErdinc Gulumsek
Erdinc Gulumsek
DODilan Damla Ozturk
Dilan Damla Ozturk
FAFatih Necip Arıcı
Fatih Necip Arıcı
BAbegüm şeyda Avci
begüm şeyda Avci
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
Aim: Contrast-induced acute kidney injury (CI-AKI) is associated with increased risk of morbidity and mortality and specific treatments are needed. In our study, we aimed to investigate the association of sodium-glucose cotransporter-2 inhibitors (SGLT2-I) use with the development of CI-AKI due to coronary angiography (CAG) in patients with DM. Methods: A total of 516 type 2 diabetes mellitus (DM) patients, including 250 SGLT2-I users and 266 non-SGLT2-I users, were included in our retrospective and cross-sectional study. Results: The study groups were divided into CI-AKI (+) and CI-AKI (-). SGLT2-I use was statistically significantly higher in the CI-AKI (-) group. Multivariate logistic regression analysis showed that SGLT2-I use reduced the probability of CI-AKI by 83.8%. Conclusion: Our findings suggest that SGLT2-Is may significantly reduce the risk of CI-AKI in diabetic patients undergoing CAG. In conclusion, the use of SGLT2-I may have a protective and preventive effect against the development of CI-AKI.

1 January 2025 in Sakarya Medical Journal
Verified
Journal Article
Open access
PDF file
HOHuseyin Ali Ozturk
Huseyin Ali Ozturk
EGErdinc Gulumsek
Erdinc Gulumsek
DODilan Damla Ozturk
Dilan Damla Ozturk
FAFatih Necip Arici
Fatih Necip Arici
BAbegüm şeyda Avci
begüm şeyda Avci
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
Aim: Diabetes mellitus (DM) is associated with the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). In our study, we aimed to evaluate the findings of MASLD and fibrosis according to liver ultrasound (USG) imaging, FIB-4 score and fibroscan findings in patients with type 2 DM followed in our internal medicine clinic. Methods: In our retrospective and cross-sectional study, 1282 patients diagnosed with type 2 DM whose anamnesis and previous examinations did not constitute an obstacle for inclusion in the study were included. The abdominal USG imaging of the patients were analysed from the system and the FIB-4 score was calculated. Liver stiffness (LS) measurements were performed with FibroScan® Mini 430 device (Echosens, France). Results: USG imaging was performed in 474 (36.9%) of 1282 patients and MASLD was diagnosed in 341 (71.9%) of these patients. FIB-4 score> was 1.3 in 45 of 341 patients diagnosed with MASLD. Fibroscan imaging was performed in 231 of 341 patients with MASLD. In 52 (22.5%) of 231 patients, LS measurements> were 8 kPa Conclusion: We recommend early screening of MASLD, which is associated with advanced fibrosis and increased cardiovascular mortality and morbidity in patients with DM, with liver USG, measurement of FIB-4 score and evaluation of LS with fibroscan in centres where possible.

Verified
Journal Article
Open access
PDF file
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
İSİhsan Solmaz
İhsan Solmaz
EAEşref Araç
Eşref Araç
IDIsmail Demir
Ismail Demir
SUSeyit Uyar
Seyit Uyar
RORamazan Azim Azim Okyay
Ramazan Azim Azim Okyay
Background: Hypertension remains the single most important modifiable risk factor for cardiovascular disease, stroke, and premature mortality worldwide. Despite major pharmacological advances, awareness, treatment, and control rates remain globally inadequate, particularly in low- and middle-income settings. Türkiye occupies a unique epidemiological position at the intersection of European and Asian cardiovascular risk patterns, with national surveys documenting a stable hypertension prevalence of approximately 30% but persistent deficits in disease control. Methods: This cross-sectional study was conducted on World Hypertension Day (17 May 2025) across nine provinces in Türkiye representing five geographic regions (Marmara, Aegean, Mediterranean, Black Sea, and Southeastern Anatolia). A total of 1967 adult volunteers were enrolled. Blood pressure was measured following standardized protocols and classified per ESH 2023 guidelines. A structured questionnaire captured sociodemographic data, lifestyle factors, medication adherence, and hypertension-related awareness. Results: The median participant age was 51 years; 55.4% were female. Screening-detected hypertension (BP ≥ 140/90 mmHg) was identified in 26.6% and above-optimal blood pressure in 41.6%. A prior hypertension diagnosis was reported by 35.1%. Among the 1277 participants without a known diagnosis, 51.1% had above-optimal or hypertension-range blood pressure readings, including 11.6% with screening-detected hypertension-range blood pressure. Independent predictors in multivariate analysis included age (OR = 1.048), male sex (OR = 1.528), BMI (OR = 1.096), and alcohol consumption (OR = 1.536); regular exercise was protective (OR = 0.796). Among known hypertensive patients, only 50% monitored blood pressure regularly, 30% skipped doses, and awareness of renal (40.4%) and visual (30.6%) complications was notably low. Conclusions: This large multi-center screening study reveals a substantial proportion of previously undetected hypertension-range blood pressure readings and persistent management gaps in a volunteer-based Turkish community sample. The observed screening rate below national prevalence averages likely reflects a healthy volunteer effect inherent to this study design. World Hypertension Day offers an effective framework for simultaneous multi-center screening. Targeted interventions should address non-cardiovascular complication awareness, sodium intake, and medication adherence.

11 September 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
AMAhmet Gazi Mustan
Ahmet Gazi Mustan
BIBektas Isik
Bektas Isik
HOHuseyin Ali Ozturk
Huseyin Ali Ozturk
FAFatih Necip Arici
Fatih Necip Arici
RORamazan Azim Azim Okyay
Ramazan Azim Azim Okyay
Although antihypertensive pharmacotherapy is well established, the treatment gaps encountered in outpatient practice — particularly drug switching, c

8 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BIBektas Isik
Bektas Isik
TTTamer Tetiker
Tamer Tetiker
Background/Objectives: Lower serum C-peptide, reflecting reduced beta-cell reserve, has been linked to diabetic complications, but whether these associations are independent of diabetes duration and glycaemic control is unclear. The objective of this study was to determine which microvascular and macrovascular complications of type 2 diabetes mellitus (T2DM) remain associated with fasting C-peptide after adjustment for these factors. Methods: In this single-centre, cross-sectional study with consecutive prospective enrolment, non-pregnant adults with an established diagnosis of T2DM attending routine outpatient follow-up were eligible; those with pancreatic malignancy or exocrine pancreatic insufficiency, monogenic or autoimmune diabetes, or acute hyperglycaemic crises were excluded. A total of 590 patients were stratified by fasting C-peptide into insufficient (<1.0 ng/mL; n = 35), borderline (1.0–1.8 ng/mL; n = 212) and normal/high (≥1.8 ng/mL; n = 343) groups. Logistic regression adjusted for age, sex, diabetes duration, HbA1c and body mass index assessed each complication. Receiver operating characteristic analysis using DeLong’s test assessed incremental discrimination. Results: In the unadjusted analyses, every complication was more frequent at lower C-peptide. After adjustment, C-peptide was not associated with the presence of albuminuria (insufficient versus normal/high, odds ratio 1.60, 95% CI 0.16–15.86) but was strongly associated with its severity: for severely increased or nephrotic-range albuminuria, the adjusted odds ratios were 13.47 (5.33–34.07) and 6.90 (3.83–12.44) in the insufficient and borderline groups (both p < 0.001). Adding C-peptide to a model of diabetes duration, HbA1c and fasting glucose was associated with a statistically significant, but modest, improvement in discrimination for severe albuminuria (area under the curve of 0.748 to 0.783; ΔAUC = 0.035, p = 0.027). Associations with macrovascular complications were present in the unadjusted analyses but were substantially attenuated after adjustment and no longer statistically significant, except for peripheral arterial disease and foot ulcer, which remained associated with insufficient C-peptide in models based on small numbers of events and should be regarded as exploratory. Conclusions: Low C-peptide was independently associated with the severity of albuminuria rather than its presence and was associated with a modest incremental improvement in discrimination. These exploratory findings suggest that C-peptide, an inexpensive and widely available measurement, may provide information associated with advanced diabetic kidney disease; prospective, externally validated studies are needed before clinical application.

Verified
Journal Article
Open access
PDF file
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
BIBektas Isik
Bektas Isik
AMAhmet Gazi Mustan
Ahmet Gazi Mustan
İAİRFAN ALİŞAN
İRFAN ALİŞAN
CECigdem Erhan
Cigdem Erhan
MKMevlut Koc
Mevlut Koc
Background: Several studies have demonstrated that adding semaglutide to the treatment of patients with type 2 diabetes mellitus (T2DM) reduces insulin requirements and glycated hemoglobin (HbA1c) levels. This study aimed to investigate real-world evidence for the effects of semaglutide dose escalation on HbA1c, body weight, dyslipidemia, and insulin dose reduction in patients with T2DM in the Cukurova region of Türkiye. Methods: This retrospective cohort study enrolled 500 patients (255 male, 245 female; mean age 56.1 ± 10.8 years) who initiated semaglutide therapy for T2DM between 2024 and 2025. Patients were grouped according to their maximum semaglutide dose: 0.25 mg (Group I), 0.50 mg (Group II), and 1.00 mg (Group III). The primary endpoint was the change in HbA1c from baseline to end of study (30 weeks) across semaglutide dose escalation groups. Secondary endpoints included changes in body weight, frequency of insulin dose reduction, and effects on lipid parameters. Results: A total of 117 patients (23.4%) discontinued semaglutide therapy, while 383 patients (76.6%) completed the study. The primary endpoint revealed a mean HbA1c reduction of −1.03 ± 0.35% from baseline to end of study (95% CI 0.99–1.07; t = 58.644; p < 0.001). Reductions in HbA1c increased progressively from Group I to Group III (HbA1c: −0.72 ± 0.28, −1.02 ± 0.26, −1.27 ± 0.34%). Insulin dose reduction frequency increased significantly from Group I to Group III (40%, 41%, and 51%, respectively; p = 0.010), with a statistically significant difference only between Group I and Group III. At the end of follow-up, rates of hypoglycemic episodes and gastrointestinal (GI) adverse events were similar across groups. Conclusions: In a real-world population from the Cukurova region of Türkiye, semaglutide dose escalation in T2DM patients achieved clinically meaningful glycemic control, body weight reduction, LDL-cholesterol lowering, and a significant increase in insulin dose reduction frequency, without a significant increase in GI adverse events.